ReviewCurrent neurology and neuroscience reports2020
Impact of Age on Multiple Sclerosis Disease Activity and Progression.
Review in Current neurology and neuroscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy of surgical interventions for trigeminal neuralgia in multiple sclerosis: A systematic review.Neurosurgical review · 2026Pooled it
- The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.Neurology and therapy · 2026Review
- International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.Neurology and therapy · 2026Review
- Assessing the reliability and validity of the Italian EQ-5D-5 L in multiple sclerosis: a cross-sectional study.Journal of patient-reported outcomes · 2026Article
- Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program.Neurology. Clinical practice · 2026Review
- Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.Journal of neurology · 2026Article
- Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.Journal of neurology · 2026Observational
- Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease.Revue neurologique · 2025Review
- Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.Neurodegenerative disease management · 2025Article
- Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older Patients.Neurology and therapy · 2025Review
- Impact of Age on Switching or Stopping Disease Modifying Therapies in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.Journal of neuroimmunology · 2025Observational
- Aging-dependent change in Th17 and cytokine response in multiple sclerosis.Journal of neuroinflammation · 2025Article
- Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.Journal of neurology · 2025Article
- The Possible Role of Metformin and Fibroblast Growth Factor-21 in Multiple Sclerosis Neuropathology: Birds of a Feather Flock Together.The European journal of neuroscience · 2025Review
- Senescent-like microglia limit remyelination through the senescence associated secretory phenotype.Nature communications · 2025Article
- First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Cellular Senescence in Glial Cells: Implications for Multiple Sclerosis.Journal of neurochemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to discuss the interaction between aging, progressive disease course, disability worsening, and treatment strategies in multiple sclerosis (MS). RECENT
findingsThe transition from the relapsing-remitting phase to the progressive phase in MS often happens in the fifth decade. In MS, structural central nervous system reserve decreases with aging and MS-associated mechanisms. While clinical and subclinical disease activity decreases with aging, the post-relapse recovery potential decreases with aging as well. Moreover, the efficacy of disease-modifying treatments declines with older age. Aging emerges as the ultimate target for prevention of progressive disease course, which is the most important determinant of disability worsening in MS. While none of our current treatment strategies targets the association between aging and progressive disease in MS, future treatment targets will likely consider the neuron-astrocyte complex, microglia, and oligodendrocyte functions impacted by the aging process.
Indexed as
Identifiers
32458308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.